These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27999054)

  • 1. Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.
    Nagu TJ; Aboud S; Matee MI; Maeurer MJ; Fawzi WW; Mugusi F
    J Antimicrob Chemother; 2017 Mar; 72(3):876-881. PubMed ID: 27999054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
    Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
    BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania.
    Shayo GA; Moshiro C; Aboud S; Bakari M; Mugusi FM
    BMC Infect Dis; 2015 Aug; 15():368. PubMed ID: 26306511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
    Robert M; Todd J; Ngowi BJ; Msuya SE; Ramadhani A; Sambu V; Jerry I; Mujuni MR; Mahande MJ; Ngocho JS; Maokola W
    BMC Infect Dis; 2020 Apr; 20(1):276. PubMed ID: 32276618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
    Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F
    BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coverage of isoniazid preventive therapy among people living with HIV; A retrospective cohort study in Tanzania (2012-2016).
    Maokola W; Ngowi B; Lawson L; Robert M; Mahande M; Todd J; Msuya S
    Int J Infect Dis; 2021 Feb; 103():562-567. PubMed ID: 33276111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993.
    Chum HJ; O'Brien RJ; Chonde TM; Graf P; Rieder HL
    AIDS; 1996 Mar; 10(3):299-309. PubMed ID: 8882670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TB drug resistance levels and patterns among Mycobacterium tuberculosis isolated from newly diagnosed cases of pulmonary tuberculosis in Dar es Salaam, Tanzania.
    Matee M; Mfinanga S; Holm-Hansen C
    APMIS; 2009 Apr; 117(4):263-7. PubMed ID: 19338514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
    Hunter OF; Kyesi F; Ahluwalia AK; Daffé ZN; Munseri P; von Reyn CF; Adams LV
    BMC Infect Dis; 2020 Oct; 20(1):738. PubMed ID: 33028260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons.
    Reddy KP; Brady MF; Gilman RH; Coronel J; Navincopa M; Ticona E; Chavez G; Sánchez E; Rojas C; Solari L; Valencia J; Pinedo Y; Benites C; Friedland JS; Moore DA
    Clin Infect Dis; 2010 Apr; 50(7):988-96. PubMed ID: 20192727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.
    van der Heijden YF; Karim F; Mufamadi G; Zako L; Chinappa T; Shepherd BE; Maruri F; Moosa MS; Sterling TR; Pym AS
    Int J Tuberc Lung Dis; 2017 Jun; 21(6):670-676. PubMed ID: 28482962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis.
    Geremew D; Endalamaw A; Negash M; Eshetie S; Tessema B
    BMC Infect Dis; 2019 May; 19(1):405. PubMed ID: 31077133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
    Kunkel A; Crawford FW; Shepherd J; Cohen T
    AIDS; 2016 Nov; 30(17):2715-2723. PubMed ID: 27782966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid preventive therapy and risk for resistant tuberculosis.
    Balcells ME; Thomas SL; Godfrey-Faussett P; Grant AD
    Emerg Infect Dis; 2006 May; 12(5):744-51. PubMed ID: 16704830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014.
    Karo B; Kohlenberg A; Hollo V; Duarte R; Fiebig L; Jackson S; Kearns C; Ködmön C; Korzeniewska-Kosela M; Papaventsis D; Solovic I; van Soolingen D; van der Werf MJ
    Euro Surveill; 2019 Mar; 24(12):. PubMed ID: 30914081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Home-Based and Facility-Based Directly Observed Therapy of Tuberculosis Treatment under Programmatic Conditions in Urban Tanzania.
    Mhimbira F; Hella J; Maroa T; Kisandu S; Chiryamkubi M; Said K; Mhalu G; Mkopi A; Mutayoba B; Reither K; Gagneux S; Fenner L
    PLoS One; 2016; 11(8):e0161171. PubMed ID: 27513331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania.
    Kibiki GS; Mulder B; Dolmans WM; de Beer JL; Boeree M; Sam N; van Soolingen D; Sola C; van der Zanden AG
    BMC Microbiol; 2007 May; 7():51. PubMed ID: 17540031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions.
    Sanchez-Padilla E; Ardizzoni E; Sauvageot D; Ahoua L; Martin A; Varaine F; Adatu-Engwau F; Akeche G; Salaniponi F; Bonnet M
    Int J Tuberc Lung Dis; 2013 Aug; 17(8):1036-42. PubMed ID: 23827027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
    Kabali C; von Reyn CF; Brooks DR; Waddell R; Mtei L; Bakari M; Matee M; Pallangyo K; Arbeit RD; Horsburgh CR
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1515-21, i. PubMed ID: 22008766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.